Market Overview

Komen-Funded Research Identifies Previously Unknown Gene Mutations Associated with Poor Outcomes in ER+ Breast Cancer

Share:

Susan G. Komen®, the world's largest nonprofit funder of breast cancer
research outside the U.S. government, today hailed work led by Komen
Scholar and Promise Grant Recipient Dr. Matthew Ellis, MB, BChir.,
Ph.D., FRCP and Komen-funded researcher Shyam Kavuri, Ph.D., which could
help improve outcomes for patients with estrogen receptor positive (ER+)
breast cancer. Their research, published today in Nature
Communications
, identified several mutations that have never before
been associated with poor outcomes in ER+ breast cancer patients –
information that could help better direct treatment and guide future
clinical trials to prevent breast cancer recurrence and mortality.

"Understanding how ER+ breast cancers develop and recur, and how to stop
them, is absolutely vital," said Victoria Wolodzko, SVP, Mission for
Komen. "This work has the potential to transform care for patients
facing ER+ disease at all stages, which will contribute significantly to
our efforts to reduce the current number of breast cancer deaths in the
U.S. by half by 2026."

"Many women and men who have faced breast cancer and have been told they
are ‘cancer-free' live in fear of their cancer returning. For some, that
fear will become a reality. It's unacceptable," said Paula Schneider,
President and CEO of Komen. "That's why we're proud to fund researchers
like Dr. Ellis who are finding new ways to identify patients at the
highest risk of poor outcomes, so we can intervene earlier and save
lives."

To date, Komen has invested more than $956 million in breakthrough
breast cancer research – the largest nonprofit breast cancer research
investment outside of the U.S. government. Read more about this
groundbreaking research from Baylor
College of Medicine
.

About Susan G. Komen®

Susan G. Komen is the world's largest breast cancer organization,
funding more breast cancer research than any other nonprofit outside of
the federal government while providing real-time help to those facing
the disease. Komen has set a Bold Goal to reduce the current number of
breast cancer deaths by 50 percent in the U.S. by 2026. Since its
founding in 1982, Komen has funded more than $956 million in research
and provided more than $2.1 billion in funding to screening, education,
treatment and psychosocial support programs serving millions of people
in more than 60 countries worldwide. Komen was founded by Nancy G.
Brinker, who promised her sister, Susan G. Komen, that she would end the
disease that claimed Suzy's life. That promise has become Komen's
promise to all people facing breast cancer. Visit komen.org
or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social.

View Comments and Join the Discussion!